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Chemotherapy is widely used as adjuvant therapy for the treatment
of squamous cell carcinoma (SCC). 5-Fluorouracil (5-FU) is
increasingly used for the treatment of SCC, though it sometimes
has a low efficacy when administered alone. However, various
drug combinations, especially 5-FU with cisplatin (CDDP), have
been effective in cancer treatment (Kish et al, 1982; Amrein and
Weitzman, 1985; Schilsky et al, 1989). Preclinical studies have
revealed that these drugs administered in combination demonstrate
synergistic anti-tumour activity (Scanlon et al, 1986; Pratesi et al,
1988; Kuroki et al, 1992).
This synergism is thought to be at least partially due to an
increase in intracellular levels of reduced folates, which potentiate
the action of 5-fluorodeoxyuridine monophosphate by forming a
covalent ternary complex with thymidylate synthase, an essential
enzyme for de novo production of the thymidine required for DNA
synthesis and repair (Scanlon et al, 1986). Other researchers
proposed that 5-FU modulated the repair of platinum-DNA
adducts through 5-FU-induced RNA damage, thereby potentiating
the anti-tumour activity of CDDP (Esaki et al, 1992). Although
these studies directly address the mechanisms by which CDDP
and 5-FU synergistically exert anti-tumour activity, it is not known
whether these anti-tumour agents can modulate anti-tumour
immunity.
Cancer cells are usually recognized and eliminated by activated
T lymphocytes. The adhesive interaction between T lymphocytes
and cancer cells is a crucial step for elimination of cancer cells.
Several cell adhesion molecules on both T lymphocytes and target
cells are believed to be important for anti-tumour immune func-
tions. Intercellular adhesion molecule-1 (ICAM-1), a member of
the immunoglobulin superfamily, is a cell adhesion molecule
expressed on various types of cancer cells. Its counter-receptor,
lymphocyte function associated antigen-1 (LFA-1), a member of
the integrin family, is expressed on T lymphocytes (Springer,
1990). The binding of ICAM-1 with LFA-1 is required for a broad
range of leucocyte functions, including T-cell-mediated killing of
cancer cells, T-helper and B lymphocyte responses, natural kill-
ing, antibody-dependent cytotoxicity mediated by monocytes and
adherence of leucocytes to endothelial cells and epithelial cells
(Martz et al, 1987; Springer et al, 1987). Thus the expression
levels of ICAM-1 on cancer cells might be critical for the elimina-
tion of cancer cells by T lymphocytes.
In this study we examined whether the anti-tumour drugs CDDP
and 5-FU, alone or in combination, can modulate the expression of
cell adhesion molecules involved in recognition of cancer cells by
T lymphocytes.
MATERIALS AND METHODS
Reagents and monoclonal antibodies (mAbs)
CDDP and 5-FU were obtained from Sigma (St Louis, MO, USA).
Unconjugated mAbs against the following human antigens were
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used in this study: anti-ICAM-1 (mouse immunoglobulin (mIg)
G2b, LB-2; Becton Dickinson, San Jose, CA, USA), anti-ICAM-2
(mIgG1, B-T1; Immunotech, Marseille, France), anti-ICAM-3
(mIgG2a, HP2/19; Immunotech, Marseille, France), anti-
vascular cell adhesion molecule-1 (VCAM-1) (mIgG1, 51-10c9;
Pharmingen, San Diego, CA, USA), anti-E-selectin (mIgG,
68-5H11; Pharmingen, San Diego, CA, USA). Staurosporin and
genistein were obtained from Wako Pure Chemicals Ltd (Tokyo,
Japan). NF-kB SN-50, an inhibitor of nuclear factor kappa B
(NF-kB) nuclear translocation, was purchased from Biomol
(Plymouth Meeting, PA, USA). Monoclonal mouse anti-human
interferon gamma (IFN-g) antibody were obtained from Genzyme
(Cambridge, MA, USA).
Cell lines and cell culture
NA and HSC-4, cancer cell lines established from patients with
SCC of the tongue, were maintained as monolayers in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% heat
inactivated fetal bovine serum (FBS), 100 units ml–1 penicillin and
100 mg ml–1 streptomycin (complete medium) (Hori et al, 1994).
Subconfluent monolayers of NA cells or HSC-4 cells were
employed in all experiments.
Cytotoxic effects of anticancer agents on NA cells
NA cells were seeded in a flat-bottomed 96-well microplate by
adding 0.2 ml of complete medium containing 3 ´ 104 cells. After
24 h incubation, NA cells were treated with various concentrations
of CDDP and/or 5-FU. After a further 18 h incubation, the
medium was removed, and cells were washed twice with phos-
phate-buffered saline (PBS), and fixed and stained for 30 min with
2% ethanol containing 0.2% crystal violet. Bound dye was eluted
with 0.1 ml of 1% sodium dodecyl sulphate. Absorbance was
measured at 570 nm on a microplate reader MR 5000 (Dynatech)
(Kamijo et al, 1989). The percentage of cytotoxicity was calcu-
lated from the mean OD by the following equation:
% cytotoxicity =
(
1–
absorbance (untreated NA cells) – absorbance (treated NA cells))
3 100
absorbance (untreated NA cells)
Flow cytometry
Antigens were detected on cell surfaces by indirect immunofluo-
rescence followed by standard flow cytometric analysis. NA cells
or HSC-4 cells (2 ´ 106 cells) were incubated in the presence or
absence of CDDP and/or 5-FU for 18 h. Cells were washed with
PBS at 4°C and incubated with 500 ng to 1 mg of primary anti-
bodies for 30 min at 4°C. Cells were washed three times with PBS
followed by a 30 min incubation with the secondary antibody,
fluoroscein isothiocyanate (FITC)-conjugated goat antimouse IgG
(Becton Dickinson, San Jose, CA, USA). Cells were washed three
times with PBS and resuspended with 100–200 ml of 1% para-
formaldehyde PBS. Samples were then analysed using a FACscan
flow cytometer (Becton Dickinson, San Jose, CA, USA). In some
experiments, cells were pretreated with genistein (100 ng ml–1),
staurosporin (10–9 M) or NF-kB SN-50 (18 mM) for 30 min before
addition of anticancer agents.
Reverse transcriptase-polymerase chain reaction
NA cells (1 ´ 106 cells) were incubated with CDDP and/or 5-FU
for 4 h. For reverse transcriptase-polymerase chain reaction
(RT-PCR) analysis, cytoplasmic RNA was extracted by the
guanidine isothiocyanate–phenol–chloroform extraction method.
To ensure that the amplification products were from the mRNA
being probed, RNA samples were treated with DNase I (Gibco
BRL, Gaithersburg, MD, USA) at room temperature for 15 min.
First-strand cDNA synthesis was carried out as described previ-
ously (Sumitani et al, 1998). Briefly, 1 mg of total RNA was
reverse transcribed to single-stranded cDNA in 25-ml of reaction
mixture containing 1 ´ RT buffer (50 mM Tris–HCl pH 8.3, 10 mM
potassium chloride, 10 mM magnesium chloride and 10 mM dithio-
threitol (DTT)), 0.5 mg of Rnasin (Promega, Madison, WI, USA),
0.5 mM of each dNTP (Pharmacia Biotech, Tokyo, Japan), 2.0 mg
of random primer and 5 units of avian myeloblastosis virus
(AMV) reverse transcriptase (Gibco BRL, Gaithersburg, MD,
USA). The reverse transcriptation reaction mixture was incubated
for 90 min at 37°C, heated at 98°C to inactivate the enzyme, and
quickly chilled to 10°C. A 5 ml aliquot of cDNA was mixed with
45 ml of PCR mixture containing 1 ´ PCR buffer, 500 mM of each
dNTP, 0.4 mM of each primer and 1 unit of Taq DNA polymerase
(Promega, Madison, WI, USA). PCR was performed using a
programmed temperature control system (Astec, Fukuoka, Japan)
set for 35 cycles of denaturation at 94°C for 1 min, annealing at
60°C for 1 min, and extension at 72°C for 2 min. A 10 ml aliquot
of each reaction mixture was electrophoresed on a 1% agarose gel,
and PCR products were visualized by ethidium bromide staining.
To normalize for the amount of input RNA, RT-PCR was
performed with primers for the constitutively expressed glycer-
aldehyde 3-phosphate dehydrogenase (GAPDH) gene.
The primers used for RT-PCR are as follows: ICAM-1: sense, 5¢
TATGGCAACGACTCCTTCT 3¢; antisense, 5¢ CATTCAGCG-
TCACCTTGG 3¢; amplified product: 238 bp. GAPDH: sense,
5¢ TGAAGGTCGGAGTCAACGGATTTGGT 3¢; antisense, 5¢
CATGTGGGCCATGAGGTCCACCAC 3¢; amplified product:
983 bp. IL-1a: sense, 5¢ CAAGGAGAGCATGGTGGTAGTAG-
CAACCAACG 3¢; antisense, 5¢ TAGTGCCGTGAGTTTCCCA-
GAAGAAGGAGG 3¢; amplified product: 491 bp. IL-1b: sense,
5¢ ATGGCAGAAGTACCTAAGCTCGC 3¢; antisense, 5¢ AC-
ACAAATTGCATGGTGAAGTCAGTT 3¢; amplified product:
801 bp. IFN-g: sense, 5¢ GCATCGTTTTGGGTTCTCTTGGCTG-
TTACTGC 3¢; antisense, 5¢ CTCCTTTTTCGCTTCCCTGTTTT-
AGCTGCTGG 3¢; amplified product: 427 bp. TNF-a: sense, 5¢
GAGTGACAAGCCTGTAGCCCATGTTGTAGCA 3¢; antisense,
5¢ GCAATGATCCCAAAGTAGACCTGCCCAGACT 3¢; ampli-
fied product: 444 bp.
Enzyme-linked immunosorbent assay
NA cells (4 ´ 104 cells in 200 ml of complete medium) were
incubated in the presence or absense of CDDP and/or 5-FU for
18 h. Aliquots of culture medium were harvested and cytokine
levels in the culture medium were determined using specific
enzyme-linked immunosorbent assay (ELISA), (Endogen, Boston,
MA, USA), according to the manufacturer’s instructions.
Electrophoretic mobility shift analysis
Electrophoretic mobility shift analysis (EMSA) was performed as
previously described (Song et al, 1997). Nuclear extracts were956 K Takizawa et al
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prepared by treating the cell pellet with cold buffer (10 mmol l–1
EGTA, 1 mmol l–1 DTT, and 0.5 mmol l–1 phenylmethylsulphonyl
fluoride (PMSF) for 15 min to allow cells to swell, and then 25 ml
10% NP-40 was added and the nuclei were pelleted. The nuclear
pellet was resuspended in buffer (20 mmol l–1 Hepes, pH 7.9,
0.4 mol l–1 sodium chloride, 1 mmol l–1 EDTA, 1 mmol l–1 EGTA,
1 mmol l–1 DTT and 1 mmol l–1 PMSF) for 15 min at 4°C. Debris
was pelleted, and supernatants were frozen at –70°C. Nuclear
extracts (5–7 mg protein) prepared from NA cells were incubated
with 50 000 cpm (0.5 ng) 32P-end-labelled double-stranded
synthetic deoxyoligonucleotide probes for 30 min at room
temperature in a 20 ml reaction volume containing 12% glycerol,
12 mmol l–1 Hepes–NaOH (pH 7.9), 60 mmol l–1 potassium chlo-
ride, 5 mmol l–1 magnesium chloride, 4 mmol l–1 Tris hydrochloride
(pH 7.9), 0.6 mmol l–1 EDTA (pH 7.9), 0.6 mmol l–1 DTT and 1 mg
poly (dI)(dC). Protein–DNA complexes were resolved in 5% native
polyacrylamide gels pre-electrophoresed for 30 min at room
temperature in 0.25 ´ TBE buffer (22.5 mM Tris–borate and
0.5 mM EDTA, pH 8.3). Gels were dried and exposed overnight to
X-ray film (Eastman Kodak, Rochester, NY, USA) with an intensi-
fying screen at –70°C. The oligonucleotide probe used in this study
to detect NF-kB was 5¢-GCTCCGGAATTTCCAAGC-3¢.
RESULTS
Cytotoxic effects of CDDP and/or 5-FU on NA cells
Both CDDP and 5-FU dose-dependently exerted cytotoxic activity
against NA cells (Figure 1). The concentration of CDDP or 5-FU
needed for 50% reduction of the OD570 in the control was approxi-
mately 500 mg ml–1. CDDP and/or 5-FU exert both cytotoxic effect
and antiproliferative effect against NA cells. Trypan blue dye
exclusion assay revealed that both agents were dominantly cyto-
toxic at concentrations exceeding 100 mg ml–1, though they were
antiproliferative and less cytotoxic for NA cells at lower con-
centrations (data not shown). For subsequent experiments, we
employed suboptimal doses of CDDP (100 mg ml–1) or 5-FU
(100 mg ml–1). When both agents (100 mg ml–1) were added simul-
taneously, no synergistic effect was observed (Figure 1). The
viabilities of NA cells treated with CDDP (100 mg ml–1) and 5-FU
(100 mg ml–1), alone or in combination, were approximately 99%
as determined by trypan blue dye exclusion assays.
Effects of CDDP and/or 5-FU on the expression of
ICAM-1, ICAM-2 and ICAM-3 on NA cells
To determine the effect of CDDP and/or 5-FU on the expression of
ICAM-1, ICAM-2 and ICAM-3 on cell surface, we employed
flow-cytometric analysis. Cell surface antigen expression on NA
cells was evaluated 18 h after incubation with CDDP and/or 5-FU,
and the results were compared to untreated control cells. As shown
in Figure 2A, ICAM-1 was constitutively expressed on untreated
NA cells (mean fluorescence intensity (MFI) was 5.44). Although
treatment with CDDP or 5-FU alone for 18 h did not induce the
expression of ICAM-1 on NA cells (MFI was 5.71 and 5.97
respectively), expression of ICAM-1 was synergistically induced
by treatment with CDDP and 5-FU (MFI was 9.52). Figures 2B
and C show that ICAM-2 or ICAM-3 are constitutively expressed
on NA cells. In contrast to the expression of ICAM-1, CDDP
and/or 5-FU did not up-regulate the levels of ICAM-2 or ICAM-3
on NA cells.
RT-PCR analysis
It was reported that ICAM-1 mRNA can be detected within a few
hours after stimulation with IFN-g in monocytes (Song et al,
1997). Therefore, the expression of ICAM-1 mRNA was exam-
ined in NA cells at 4 h after incubation with CDDP and/or 5-FU.
To evaluate the effect of CDDP and/or 5-FU on the expression of
ICAM-1 mRNA in NA cells, we employed RT-PCR method.
RT-PCR analysis revealed that the expression of ICAM-1 mRNA
was synergistically induced by CDDP and 5-FU in NA cells,
whereas CDDP or 5-FU alone did not induce ICAM-1 mRNA
expression (Figure 3A). Densitometrical analysis confirmed the
synergistic induction of ICAM-1 mRNA in NA cells treated with
CDDP and 5-FU (Figure 3B).
Effects of protein kinase inhibitors on the expression of
ICAM-1 induced by CDDP and/or 5-FU
To determine whether ICAM-1 induction by CDDP and 5-FU is
related to protein phosphorylation, NA cells were pretreated with
genistein (100 ng ml–1) or staurosporin (10–9 M) for 30 min. After
pretreatment, cells were incubated with CDDP and 5-FU for 18 h,
and the expression of ICAM-1 on NA cells were analysed by flow
cytometry. Induction of ICAM-1 on NA cells by CDDP and 5-FU
was inhibited by the pretreatment with genistein, though pretreat-
ment with staurosporin did not alter ICAM-1 expression on NA
cells (Figure 4).
Effects of CDDP and 5-FU on DNA binding activity on
ICAM-1 NF-kB
The ICAM-1 promoter contains NF-kB sites located distal
(nucleotides –540 to –528) and proximal (nucleotides –228 to
–217) (Song et al, 1997). We employed EMSA to examine
whether CDDP and 5-FU induces NF-kB binding activity in NA
cells, since recent data indicate that IFN-g, a potent inducer of
ICAM-1 on epithelial cells, increases DNA binding activity of the
proximal NF-kB site (Song et al, 1997). Treatment with CDDP
and 5-FU increased DNA binding activity of the proximal NF-kB
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Figure 1 Cytotoxicity of anticancer agents on NA cells. NA cells were
incubated in the presence of various concentrations of CDDP and/or 5-FU for
18 h. Percent cytotoxicity was determined as described in Materials and
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site (Figure 5), and pretreatment with genistein for 30 min did not
inhibit this increase in binding activity (Figure 5). These results
demonstrate that CDDP and 5-FU can increase the NF-kB binding
activity of the ICAM-1 promoter in NA cells, and this binding
activity cannot be inhibited by genistein.
Effect of the inhibitor of NF-kB nuclear translocation on
the CDDP and 5-FU-induced ICAM-1 expression on NA
cells
To further investigate the involvement of NF-kB on the induction
of ICAM-1 expression by CDDP and 5-FU, NA cells were treated
with CDDP and 5-FU in the presence of NF-kB SN-50, a NF-kB
nuclear translocation inhibitor, for 18 h. After incubation, the
expression levels of ICAM-1 on NA cells were flow cytometri-
cally analysed using a FACscan flow cytometer. Incubation of NA
cells with NF-kB SN-50 did not inhibit CDDP and 5-FU-induced
ICAM-1 expression (data not shown).
Effects of CDDP and/or 5-FU on cytokine production by
NA cells
ICAM-1 is induced by various stimuli including interleukin-1 (IL-
1), tumour necrosis factor-a (TNF-a) and IFN-g. We examined the
effects of CDDP and/or 5-FU on the production of these cytokines
by NA cells. NA cells were cultured in the presence or absence of
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Figure 2 Effects of anticancer agents on the expression of ICAM-1, ICAM-2 and ICAM-3 on NA cells. NA cells were incubated with CDDP (100 mg ml–1) and/or
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CDDP and/or 5-FU for 18 h, and IL-1a, IL-1b, TNF-a and IFN-g
levels in the culture medium were determined by ELISA. All
cytokines tested were undetectable in the culture medium of
NA cells treated with CDDP and/or 5-FU (data not shown).
Accordingly, we employed RT-PCR for analysis of cytokine
mRNA levels in NA cells. As shown in Figure 6, IL-1a mRNA
and TNF-a mRNA were detectable in untreated NA cells.
However, mRNA levels of these cytokines were not up-regulated
by treatment with CDDP and/or 5-FU. IL-1b mRNA was
undetectable in the total RNA samples extracted from the NA cells
treated with CDDP and/or 5-FU (data not shown). Although IFN-g
mRNA level was not induced by CDDP or 5-FU alone, it was
synergistically upregulated by simultaneous treatment with CDDP
and 5-FU (Figure 6). Then the effect of CDDP and 5-FU on the
expression of ICAM-1 on NA cells were examined in the presence
of monoclonal antibody against human IFN-g. NA cells were
treated with CDDP and 5-FU for 18 h in the presence of
monoclonal antibody against IFN-g, and the expression of ICAM-
1 on NA cells was examined by flow-cytometry. Monoclonal anti-
body against IFN-g could not inhibit the induction of ICAM-1 by
CDDP and 5-FU on NA cells (data not shown).
Effects of CDDP and/or 5-FU on the expression of
E-selectin and VCAM-1 on NA cells
The expression of E-selectin and VCAM-1 were evaluated 18 h after
incubation with CDDP and/or 5-FU, and compared to levels in
untreated cells. As shown in Figure 7A, E-selectin was constitutively
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GAPDH
12 34
A
2.5
2
1.5
1
0.5
0
I
C
A
M
-
1
 
m
R
N
A
 
f
o
l
d
 
I
n
c
r
e
a
s
e
Control
CDDP
5-FU
CDDP+5-FU
B
Figure 3 (A) RT-PCR analysis of ICAM-1 mRNA expression in NA cells treated with anticancer agents. NA cells (1 ´ 106) were incubated with CDDP
(100 mg ml–1) and/or 5-FU (100 mg ml–1) for 4 h. Total RNA was extracted, and RT-PCR analysis was performed as described in Materials and Methods. Lane 1,
control; lane 2, CDDP; lane 3, 5-FU; lane 4, CDDP and 5 FU. (B) Normalized absorption values were obtained by densitometry scanning of ICAM-1 and
GAPDH mRNA bands. From the ratio of ICAM-1 to GAPDH, the fold increase over untreated control cells was calculated
Negative
control
Control
CDDP + 5-FU
+ genistein
CDDP + 5-FU
R
e
l
a
t
i
v
e
 
c
e
l
l
 
n
u
m
b
e
r
A
Fluoresence intensity
Negative
control
Control CDDP + 5-FU
+ staurosporin
CDDP + 5-FU
R
e
l
a
t
i
v
e
 
c
e
l
l
 
n
u
m
b
e
r
B
Fluoresence intensity
Figure 4 Effects of protein kinase inhibitors on the expression of ICAM-1 induced by CDDP and 5-FU. NA cells were pretreated with genistein (A) or
staurosporin (B) for 30 min before addition of anticancer agents. After incubaton with CDDP and 5-FU for 18 h, the expression of ICAM-1 on NA cells was
analysed by a FACscan flow cytometry as described in Materials and Methods. Negative controls without primary antibody are also shownEffects of CDDP and 5-FU on ICAM-1 expression 959
British Journal of Cancer (1999) 80(7), 954–963 © 1999 Cancer Research Campaign 
14 3 2
IL-1a
TNF-a
IFN-g
GAPDH
1234 Figure 5 Electrophoretic mobility shift analysis of nuclear extract prepared
from NA cells. After the pretreatment with (lane 3, 4) or without genistein
(100 ng ml–1, lane 1, 2), NA cells were treated with CDDP (100 mg ml–1) and
5-FU (100 mg ml–1) for 30 min (lane 2, 4), and nuclear extracts were
prepared. Radiolabelled oligonucleotide comprising the proximal ICAM-1 NF-
kB site was incubated with 5 mg of nuclear extracts as described in Materials
and Methods, and the amounts of specific NF-kB binding complexes were
compared to control nuclear extracts
Figure 6 RT-PCR analysis of cytokine mRNA expression in NA cells
treated with anticancer agents. NA cells (1 ´ 106) were incubated with CDDP
(100 mg ml–1) and/or 5-FU (100 mg ml–1) for 4 h. Total RNA was extracted, and
RT-PCR analysis was performed as described in Materials and Methods.
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expressed on control cells. Treatment with CDDP or 5-FU slightly
induced the expression of E-selectin on NA cells, and expression of
E-selectin was additively induced by treatment with CDDP and 5-
FU. Similar results were obtained for VCAM-1 expression on NA
cells (Figure 7B).
Effects of CDDP and/or 5-FU on the expression of
ICAM-1, ICAM-2 and ICAM-3 on HSC-4 cells
To confirm that the synergistic effects of CDDP and 5-FU reported
in this study are not specific to NA cells, the effects of CDDP
and/or 5-FU on the expression of ICAM-1, ICAM-2 and ICAM-3
on HSC-4 cells were examined. Since HSC-4 cells were more
sensitive for cytotoxicity induced by CDDP and/or 5-FU than NA
cells, HSC-4 cells were incubated in the presence of CDDP
(10 mg ml–1) and 5-FU (100 mg ml–1) for 18 h, and cell surface
antigen expression on HSC-4 cells was evaluated. As shown in
Figure 8A, ICAM-1 was constitutively expressed on untreated
HSC-4 cells (MFI was 6.80). Although CDDP or 5-FU alone did
not induce the expression of ICAM-1 on HSC-4 cells (MFI was
9.21 and 10.63 respectively), expression of ICAM-1 was synergis-
tically induced by treatment with CDDP and 5-FU (MFI was
20.34). Figures 8B and C show that ICAM-2 or ICAM-3 are
constitutively expressed on HSC-4 cells. In contrast to the expres-
sion of ICAM-1, CDDP and/or 5-FU did not up-regulate the levels
of ICAM-2 or ICAM-3 on HSC-4 cells.
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DISCUSSION
Although the principal mechanism of anticancer drugs to eliminate
cancer cells is induction of apoptosis (Huschtscha et al, 1996;
Ueda et al, 1997), mechanisms to eliminate cancer cells which has
escaped from apoptosis, including activation of the host immune
system, might also play a role. Previous studies have shown
mechanisms by which CDDP and 5-FU synergistically exert anti-
tumour activity (Scanlon et al, 1986; Esaki et al, 1992), but it is not
known whether these agents can stimulate the host immune
system.
Macrophages and T lymphocytes play essential roles in defence
against cancer cells. Exclusion of cancer cells in vivo involves
several cytotoxic effector mechanisms. For example, secretion of
nitric oxide (NO), an unstable free radical gas, is nominated as a
major effector molecule for macrophage cytotoxicity. We have
recently reported that NO is essential for host immune responses
against infectious agents and cancer cells (Kamijo et al 1993a,
1993b, 1994; Sumitani et al, 1997). Cytolytic T-cells must recog-
nize antigens presented by MHC class I molecules or certain cell
adhesion molecules to be effective (Vanky et al, 1990). ICAM-1,
an immunoglobulin supergene family member, is found on
lymphocytes and monocytes and can be induced on endothelial
cells by cytokines, such as IL-1, TNF and IFN (Pohlman et al,
1986; Staunton et al, 1988; Buckle and Hogg, 1990; Springer et al,
1990; Most et al, 1992). Several studies (Vanky et al, 1990;
Bouillon et al, 1991; Webb et al, 1991; Ferrini et al, 1994) have
indicated that ICAM-1 expression on tumour cells is important for
host immune, cell-mediated cytotoxicity. For example, cytokines
such as IFN, TNF and IL-1 are able to increase ICAM-1 expres-
sion in cancer cell lines in vitro (e.g. HT-29 human colon tumour
cells) and are reported to render the cells susceptible to
macrophage-mediated killing (Webb et al, 1991). Co-recognition
of ICAM-1 and MHC class I is a vital for host cell-mediated
tumour cytotoxicity (Vanky et al, 1990).
According to previous reports, CDDP does not alter the expres-
sion of cell adhesion molecules on tumour cells (Yamaue et al,
1991; Mizutani et al, 1993). In contrast, it is reported that a combi-
nation of CDDP and mitomycin C increases the expression of cell
adhesion molecules on Daudi and KATO-III cells (Ishihata et al,
1996). Our results demonstrate that combined treatment with
CDDP and 5-FU can elevate the expression of ICAM-1 in a cancer
cell line, suggesting that the clinically accepted synergistic anti-
tumour effects of CDDP and 5-FU might be, at least partly,
mediated by increasing antigen presentation to T-cells.
We also have shown that ICAM-2 and ICAM-3 expression on
NA cells is not induced by CDDP and 5-FU. Both ICAM-2 and
ICAM-3 bind to LFA-1 on T lymphocytes and activate them, but
the activating signals transduced by ICAM-2 and ICAM-3 are
weaker than ICAM-1. Thus, induction of ICAM-1 on cancer cells
might be more important than induction of ICAM-2 or ICAM-3. In
this regard, specific induction of ICAM-1 on cancer cells by
CDDP and 5-FU is beneficial in generating optimal antigen
presentation of cancer cells to T lymphocytes.
The synergistic effects of CDDP and 5-FU reported in this study
are not specific to NA cells, since ICAM-1, not ICAM-2 and
ICAM-3, was synergistically induced by CDDP and 5-FU on
HSC-4 cells.
In this study, we also investigated the mechanisms by which
CDDP and 5-FU induce the expression of ICAM-1 on cancer cells.
Treatment of NA cells with genistein, a protein tyrosine kinase
(PTK) inhibitor, resulted in abolishment of CDDP and 5-FU-induced
ICAM-1 expression, whereas treatment with staurosporin, a protein
kinase C inhibitor, did not inhibit ICAM-1 expression induced by
CDDP and 5-FU. These results suggest that CDDP and 5-FU
induced ICAM-1 expression via a tyrosine related pathway, though
further experiments are necessary to isolate the exact mechanism.
We have shown that ICAM-1 regulation by CDDP and 5-FU
occurs at the mRNA level. This observation suggests that CDDP
and 5-FU target transcription factors interacting with ICAM-1
promoter elements. Previous reports have indicated that ICAM-1
expression is transcriptionally regulated, and the promoter
contains binding sites for transcription factors such as NF-kB,
AP-1 and C/EBP (Voraberger et al, 1991; Wawryk et al, 1991;
Look et al, 1994). Our results indicate that CDDP and 5-FU
caused the accumulation of nuclear factor binding to proximal
ICAM-1 NF-kB sites. However, suppression of NF-kB nuclear
translocation by the inhibitor did not inhibit CDDP and 5-FU-
induced ICAM-1 up-regulation. Furthermore, pretreatment with
genistein did not reduce the formation of the specific NF-kB
binding complex. These results suggest that NF-kB is not
important for CDDP and 5-FU synergistic induction of ICAM-1
expression on cancer cells. Future experiments using transfection
of the ICAM-1 promoter elements should determine if CDDP and
5-FU-induced ICAM-1 expression is regulated by NF-kB.
An alternative explanation for up-regulation of ICAM-1 may be
via an autocrine mechanism involving cytokine. Epithelial cancer
cells can produce some cytokines including IL-1a, IL-1b, TNF-a
and IFN-g, and they are reportedly able to induce the expression of
ICAM-1 in various types of cells. Thus, NA cells stimulated by
CDDP and 5-FU may secret these cytokines, which in turn stimu-
late NA cells in an autocrine manner to induce the expression of
ICAM-1. However, treatment with CDDP and 5-FU did not induce
production of either IL-1a, IL-1b or TNF-a in NA cells, as deter-
mined by ELISA and RT-PCR analysis. Thus, IL-1a, IL-1b and
TNF-a are not involved in up-regulation of ICAM-1. In contrast,
IFN-g mRNA level was up-regulated by simultaneous treatment
with CDDP and 5-FU. However, IFN-g may not be responsible for
induction of ICAM-1, since induction of ICAM-1 by CDDP and
5-FU was not inhibited by monoclonal antibody against IFN-g.
The results of the present study further demonstrate that
combined treatment with CDDP and 5-FU directly effects the
expression and function of certain molecules engaged in cell–cell
recognition and signalling on the surfaces of tumour cells.
E-selectin and VCAM-1 are cell adhesion molecules mainly
expressed on endothelial cells. They bind to their counter-
receptors on cancer cells, and mediate the adhesion of cancer cells
to endothelium (Rice and Bevilacqua, 1989; Lauri et al, 1991;
Majuri et al, 1992). Previous reports have indicated that the
expression of sialyl Lex and sialyl Lea, counter-receptors for
E-selectin, and very late antigen-4 (VLA-4), counter-receptor
for VCAM-1, on cancer cells is closely related to their metastatic
properties (Majuri et al, 1992; Iwai et al, 1993). Although much
attention has been paid to the expression of these cell adhesion
molecules on cancer cells, less is known about the expression of E-
selectin or VCAM-1 on cancer cells. Interestingly, the expression
of E-selectin and VCAM-1 on NA cells was up-regulated by
combined treatment with CDDP and 5-FU, though the signifi-
cance of the induced expression, as well as the functions of these
cell adhesion molecules on NA cells, is not clear.
Recently, the existence of soluble forms of ICAM-1 has been
demonstrated in the serum of normal subjects, patients with962 K Takizawa et al
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autoimmune diseases, transplant rejection and malignancies. The
increase in ICAM-1 serum levels in various neoplastic process has
been associated with an unfavourable prognosis (Sanchez-Rovita
et al, 1998). The effect of CDDP and 5-FU on the level of soluble
ICAM-1 in serum of patients with cancer remains to be examined.
Increased expression of ICAM-1 on cancer cells by treatment with
these anticancer agents suggests they can function as an immune
modulator. Their effectiveness as cancer therapeutic agents may be
increased if they increase the expression of ICAM-1 on cancer
cells without increasing soluble ICAM-1 level.
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